Zenas BioPharma, is selling at 8.33 as of the 21st of March 2025; that is 2.23 percent decrease since the beginning of the trading day. The etf's open price was 8.52. Zenas BioPharma, has about a 38 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States. More on Zenas BioPharma, Common
Zenas BioPharma, Common [ZBIO] is traded in USA and was established 2015-06-22. Zenas BioPharma, is listed under Pharmaceutical Products category by Fama And French industry classification. The fund is listed under Health Care category and is part of Biotechnology family. Zenas BioPharma, Common at this time have 369.97 M in net assets. , while the total return for the last 3 years was -33.04%.
Zenas BioPharma, generates negative cash flow from operations
Check Zenas BioPharma, Probability Of Bankruptcy
Zenas BioPharma, Common Risk Profiles
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Zenas BioPharma,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.